Notes on the Human Papillomavirus (HPV) Vaccine in Pediatrics

Notes on the Human Papillomavirus (HPV) Vaccine in Pediatrics HPV vaccines are approximately ۹۷% immunogenic, with higher immunogenicity in those aged ۹ to ۱۵ years than in those aged ۱۶ to ۲۶ years. The vaccine is most effective when administered before any exposure to the virus types, significantly reducing the prevalence of infection with the vaccine virus types, as well as reducing anogenital warts and cervical precancers caused by the vaccine virus types. According to the AAP, the HPV vaccine should be administered to all children aged ۹ to ۱۲. if not administered by age of ۲۶, it should be administered following catch up guidelines. It may be administered from age ۲۷ to ۴۵, based on the individual's circumstances and consultation. If vaccination begins before age ۱۵, two doses spaced ۶ to ۱۲ months apart are enough. If started after age ۱۵, three doses should be administered at ۰, ۱-۲, and six months. If the vaccination series was completed with the ۲- or ۴-valent vaccine, there is no recommendation for an additional dose of the ۹-valent vaccine. If a person has been previously exposed to the virus, is currently infected, has anogenital warts or cervical lesions or abnormal Pap test results, there is no contraindication to receiving the vaccine. In fact it is recommended to prevent other virus types in the vaccine. This vaccine can be administered alongside other live and non-live vaccines. Because this vaccine is non-live, it can be administered to immunocompromised patients, but it must be administered in ۳ doses at any age. Side effects of this vaccine are minor and include local reactions such as pain, swelling, and redness at the injection site as well as systemic reactions such as fever, headache, malaise and fatigue. Cases of syncope and fainting have been reported during vaccination, so individuals should be monitored for at least ۱۵ minutes after the injection. They should remain in a sitting or lying position to prevent injury in case of syncope. This vaccine should not be administered during pregnancy due to insufficient information. However, a pregnancy test is not required before administration. Vaccination is safe during breastfeeding. The only absolute contraindication to this vaccine is an immediate hypersensitivity reaction to the vaccine or its components, as well as to yeast, as this vaccine is produced in yeast.